Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
20 April 2025
| Name: | NOVOGEN LIMITED (NRT) (This company subsequently changed its name and is now KAZIA THERAPEUTICS LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 01 September 1994 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now KAZIA THERAPEUTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now KAZIA THERAPEUTICS LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now KAZIA THERAPEUTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| KAZIA THERAPEUTICS LIMITED | 29/11/2017 | |
| NOVOGEN LIMITED | 13/05/1997 | 29/11/2017 |
| NORVET LIMITED | 13/05/1997 |
REGISTRY:
Computershare Sydney
6 Hope St Ermington NSW 2115
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail
name changed to Kazia Therapeutics Limited | 29/11/2017 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 24/11/2017 |
The suspension of trading in the securities of Novogen Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the completion of a capital raising. Security Code: NRT | 12/11/2014 |
the Closing Date of its current capital raising using the ASX BookBuild Facility has been extended from today Friday 7 November 2014 at 3 pm, to next Tuesday 11 November 2014 | 07/11/2014 |
has received confirmation that its experimental drug product, Cantrixil, has passed its final pre-clinical test of efficacy as evidence of its potential to significantly improve the survival prospects of patients with late-stage ovarian cancer | 06/11/2014 |
The securities of Novogen Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to a placement. Security Code: NRT | 05/11/2014 |
we understand that on or about this date the company made an in specie distribution of 3 shares in MEI Pharma, Inc for every 40 shares in the company | 27/11/2012 |
name changed from Norvet Limited | 13/05/1997 |
name changed to Kazia Therapeutics Limited | 29/11/2017 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 24/11/2017 |
The suspension of trading in the securities of Novogen Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the completion of a capital raising. Security Code: NRT | 12/11/2014 |
the Closing Date of its current capital raising using the ASX BookBuild Facility has been extended from today Friday 7 November 2014 at 3 pm, to next Tuesday 11 November 2014 | 07/11/2014 |
has received confirmation that its experimental drug product, Cantrixil, has passed its final pre-clinical test of efficacy as evidence of its potential to significantly improve the survival prospects of patients with late-stage ovarian cancer | 06/11/2014 |
The securities of Novogen Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to a placement. Security Code: NRT | 05/11/2014 |
we understand that on or about this date the company made an in specie distribution of 3 shares in MEI Pharma, Inc for every 40 shares in the company | 27/11/2012 |
name changed from Norvet Limited | 13/05/1997 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 27/06/2017 | Bryce Carmine | 600,000 | $0.049 | $29,400 | |
| 14/06/2017 | Iain Ross | 1,000,000 | $0.055 | $55,005 | |
| 13/06/2017 | Steven Coffey | 320,000 | $0.057 | $18,240 | |
| 13/06/2017 | James Garner | 125,000 | $0.057 | $7,125 | |
| 24/02/2017 | Steven Coffey | 100,000 | $0.086 | $8,550 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Iain Ross | Non Exec Chairman | 22/07/2015 |
| Mark Hinze | CFO | 18/06/2010 |
| Steven Coffey | Non Exec Director | 08/11/2012 |
| Bryce Carmine | Non Exec Director | 03/06/2015 |
| James Garner | Executive Director, CEO | 01/02/2016 |
| Kate Hill | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| John O'Connor | Non Exec Chairman | 25/05/2012 | 08/06/2017 |
| Ian Phillips | Non Exec Director | 03/06/2015 | 08/06/2017 |
| Peter Gunning | Non Exec Director | 04/03/2014 | 05/09/2016 |
| Christopher Cox | Executive Director, CEO | 07/12/2012 | 22/07/2015 |
| Robert Birch | Deputy Chairman, Non Exec Director | 12/12/2012 | 04/03/2014 |
| Andrew Heaton | Executive Director | 07/12/2012 | 04/03/2014 |
| Josiah Austin | Non Exec Director | 20/09/2010 | 19/04/2013 |
| William Rueckert | Chairman | 23/03/2009 | 07/12/2012 |
| Peter White | Non Exec Director | 20/09/2010 | 07/12/2012 |
| Ross Youngman | Non Exec Director | 20/09/2010 | 08/11/2012 |
| Peter Scutt | Non Exec Director | 29/10/2010 | 25/05/2012 |
| Geoffrey Leppinus | Non Exec Director | 24/02/2005 | 29/10/2010 |
| Philip Johnston | Non Exec Chairman | 01/01/1997 | 18/10/2010 |
| Christopher Naughton | Managing Director, CEO | 01/03/1997 | 01/12/2009 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
